Future and Growth For Bone Densitometer Market

Bone densitometer is a medical device designed to accurately measure bone density.

It is primarily use in the detection of metabolic bone diseases, such as osteoporosis, which are characterized by low bone mineral density and high risk of fractures.Bone densitometry involves use of limited dose of ionizing radiation that produces bone images, typically of lower spine and hips, to accurately estimate bone loss.

DEXA is one of the simple and noninvasive technologies used in bone densitometers.The global bone densitometers market size is expected to reach USD 1.2 billion by 2025, according to a new study by Grand View Research, Inc.

The growing prevalence of metabolic bone diseases is believed to be responsible for the high clinical urgency to adopt bone densitometers, thereby impelling the market demand.

Growing base of geriatric and obese population, which is highly susceptible to developing disorders such as osteoporosis, is anticipated to propel the demand further.

The aforementioned factors are slated to present the market with lucrative growth opportunities over the coming years.Moreover, presence of consistent number of health initiatives to promote awareness pertaining to osteoporosis is anticipated to broaden market growth potential over the coming years.

Cell Therapy Market OverviewGlobal cell therapy market size is expected to exhibit a CAGR of 22.36% over the forecast period from 2017 to 2023, according to the latest research report from Market Research Future (MRFR).Cell Therapy Market Competitive Analysis:Leading players in the global cell therapy market include AlloCure, Arteriocyte Medical Systems, Athersys Inc., Baxter Healthcare Corporation, Bone Therapeutics, Celgene Corporation, Cell Medica, Cellerant Therapeutics, Fibrocell, and Forticell Bioscience.In August 2019, MIT researchers came up with a method to improve the outcomes of a CAR T-cell therapy for oncological applications.

Using a vaccine to boost the number of anti-cancerous T cells, the new method has been shown to be effective against solid tumors.Cell Therapy Market Segmentation:The global cell therapy market is segmented on the basis of type, product, technique, technology, cell source, application, end use, and region.By type, the global cell therapy market is segmented into autologous and allogeneic.

The autologous segment is likely to dominate the global cell therapy market over the forecast period.By product, the global cell therapy market is segmented into consumables, equipment, and software and other services.By technique, the global cell therapy market is segmented into stem cell therapy, cell vaccine, adoptive cell transfer, fibroblast cell therapy, and chondrocyte cell therapy.By technology, the global cell therapy market is segmented into viral vector technology, cell immortalization technology, and genome editing technology.By cell source, the market is segmented into bone marrow, adipose tissue, and umbilical cord blood-derived cells.By application, the global market is segmented into oncology, CVD, orthopaedic, and wound healing.By end use, the global cell therapy market is segmented into hospitals and clinics, regenerative medicine centers, and research institutes.Cell Therapy Market Regional Analysis:The global cell therapy market is likely to be dominated by the Americas regional segment over the forecast period due to the increasing demand for cell therapy in the highly advanced healthcare sector in North America.

North America is likely to dominate the global cell therapy market over the forecast period due to the growing development in the field of cell therapy and the increasing demand for advanced remedial solutions such as cell therapy.

The presence of leading players in the cell therapy market in the region is also a major driver for the cell therapy market in North America and is likely to propel smooth growth of the market in the region over the forecast period.The Americas region accounted for a dominant 37.6% of the global cell therapy market in 2017 and is expected to exhibit a robust 21.45% CAGR over the forecast period.Europe is also likely to exhibit smooth growth in the global cell therapy market in the coming years due to the increasing demand for advanced healthcare methodologies such as cell therapy.

Cell therapy requires the use of highly advanced genetic engineering processes in order to make the full use of the technology’s potential, leading to the presence of several leading market players in the region to be manifested as a major driver for the cell therapy market in Europe.

Global Bone Densitometer Devices Market Synopsis:The report covers a forecast and an analysis of the Bone Densitometer Devices Market on a global and regional level.

The study provides historical data for 2015, 2016, 2017 and 2018 along with a forecast from 2020 to 2025 based on revenue (USD Million) and volume (Kilotons).

The study includes drivers and restraints of the Bone Densitometer Devices Market along with the impact they have on the demand over the forecast period.

Additionally, the report includes the study of opportunities available in the Bone Densitometer Devices Market on a global level.The Global Bone Densitometer Devices Market is expected to growing at a CAGR of 3.55% in the forecast period of 2021 to 2028.Available Exclusive Sample Copy of this Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-bone-densitometer-devices-market .According to the market report analysis, Bone Densitometer Devices are the medical devices that used for diagnosing osteoporosis.

The bone densitometer devices are used to measure the calcium concentration in the bones and measure the bone density.

Additionally, increasing prevalence of osteoporosis, increased focus on research and development proficiencies in regards to medical devices and on the adoption of advanced healthcare technologies, ever-rising geriatric population and rising expenditure on the healthcare infrastructure development especially in the developing economies are the major factors attributable to the growth of Bone Densitometer Devices Market.In terms of the regional analysis, North America dominates the Bone Densitometer Devices Market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period.

Global Bone Biopsy Market Research Report: Information by Type (Needle Biopsy and Open Biopsy), Guidance (MRI Guided and CT Guided), and End Users (Hospitals and Clinics, Surgical Centers, and Others), and Region (Americas, Europe, Asia-Pacific, Middle East & Africa)— Forecast till 2027Market HighlightsBone biopsy is performed to diagnose various bone disorders such as bone cancer, bone infection, osteoporosis and chronic kidney disease.

Nowadays, biopsy procedure has received great importance in oncology as one of the promising methods in cancer diagnostics.

The demand for needle biopsy is found to be increasing from last few years.Increasing prevalence of chronic diseases such as Chronic Kidney Disease (CKD) and demand new diagnostic services drives the market growth.

Additionally, increasing research and development activities, technological advancements to identify the causes and risk factors associated with osteopenia and osteoporosis also fuel the market growth of global market.The global Bone biopsy market is expected to grow at a CAGR of 5.7% during the forecast period.Taste the market data and market information presented through more than 55 market data tables and figures spread over 101 pages of the project report.

Avail the in-depth table of content (TOC) & market synopsis on “Bone biopsy market research report–Global forecast till 2023.”Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/5341Major Players in the MarketSome of the key players in the global market are C R Bard (U.S.), Becton, Dickinson and Company (U.S.), B. Braun Melsungen AG, Hologic, Inc. (U.S.), Cook Medical (U.S.), Devicor Medical Products Inc. (U.S.), Argon Medical Inc. (U.S.), and othersRegional AnalysisAmerica is the largest market for bone biopsy owing to the rising prevalence of bone cancer and osteoporosis along with other bone disorders, extensive use of diagnostic services in hospitals & surgical centers and increasing importance of early diagnosis of bone cancer.

According to the Centers for Disease Control and Prevention (2015) in the U.S., 4.9 million adults were diagnosed with kidney disease.

Bone Cancer Market Research Report: Information by Type (Ewing Sarcoma and Osteosarcoma, Chondrosarcoma and Chordoma), Diagnostic Test & Treatment (CT, MRI, Cisplatin, Doxorubicin and Cyclophosphamide), End User (Hospitals & Clinics, Diagnostic Centres and Academic & Research Organizations) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Global Forecast till 2025Bone Cancer Market – HighlightsBone cancer is cancer of the bones.

Bone tumors may be painless or accompanied by a dull, aching pain.The low level of pain in bone cancer can make it more difficult to identify and diagnose than other types of cancer, as the patient may ignore the pain for some time.

Bone cancer is seen to be most prevalence in the age group of 19-40, although other age groups are also susceptible to the disease.

The disease is caused by continuous exposure to radiation or abnormal healing of a bone injury.

The tumor forms when the cell division within bones gets out of control, resulting in mutations and cancerous cells.The global Bone Cancer Treatment is likely to be driven by the growing awareness about bone cancer and the increasing efforts being taken to eradicate cancer.

The increasing government support to cancer treatment research is likely to be a major driver for the global bone cancer market over the forecast period, as cancer has emerged as a major health problem in recent years and is likely to remain among the major problems facing the healthcare sector over the forecast period.Competitive Analysis:Leading players in the global bone cancer market include AstraZeneca PLC, Actavis PLC, Celgene Corporation, F. Hoffman-La Roche, Novartis International AG, Sanofi SA, Pfizer Inc., GlaxoSmithKline PLC, Eli Lilly and Co., Bristol-Myers Squibb, and Amgen Inc.Industry Updates:In January 2019, researchers at the University of Missouri developed a precision medicine for treating bone cancer in dogs by using the dog’s tumor to produce the relevant therapy.

Bone Biopsy Market – OverviewThe increased cancer detection rate is a major factor adding to the expansion of the market of bone biopsy.

Reports that examines the healthcare industry has been offered by Market Research Future, which produces reports on industry verticals that evaluate the market development and opportunities.

By end-user, the bone biopsy market is segmented into surgical centers, hospital & clinics, diagnostic centers, and others.

The APAC regional market is anticipated to expand at the fastest pace and is guided by the high occurrence of chronic diseases such as obesity, kidney disease, diabetes, and others.

Japan, India China are major contributors to the growth of the market.This growth is attributed to escalating demand for technologically advanced medical devices in diagnostic centers and the availability of highly qualified medical professional devoted to research in oncology.

In the MEA region, the United Arab Emirates gains the largest market share for bone biopsy due to the accessibility to better healthcare infrastructure and extensive scope for research.Competitive AnalysisThe development of the alternative courses of action in terms of both their expenses and consequences are steering the growth of the market.